InViragen: Agreemnent with Shantha Bio

InViragen (Ft. Collins), who is developing vaccines against emerging world-wide diseases such as West Nile, avian influenza, plague and smallpox, has announced a vaccine manufacturing agreement with Shantha Biotechnics (Hyderabad, India) to develop their lead dengue vax product to enable completion of preclinical studies and initiate safety and efficacy clinical trials.

Since winning the first Faegre & Benson Venture Showcase Award at the 2005 BioWest Conference in Denver, led by Dan Stinchcomb, President & CEO, InViragen has continued to meet milestones.

Dengue viruses threaten over one third of the world’s population, and cause an estimated 100 – 150 million cases of dengue fever every year. Inviragen’s dengue vaccine was designed by collaborators at the Centers for Disease Control and Prevention to protect against all four of the dengue viruses. The vaccine has been shown to be safe and effective in preclinical animal models.